Bibliography
- MATSUKURA M, KOIKE K, ZON G: Antisense phosphorothioates as antivirals against human immunodeficiency virus (HIV) and hepatitis B. Toxicol. Lett. (1995) 82–83:435–438.
- KRIEG AM, MATSON S, FISHER E: Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. Antisense Nucleic Acid Drug Dev. (1996) 6(2):133–139.
- NYCE JVV, METZGER WJ: Antisense DNA for asthma in an animal model. Nature (1997) 385:721–725.
- NYCE JW: Respirable antisense oligonucleotides (rASONs) for asthma. Exp. Opin. Invest.Drugs (1997) 6(9):1149–1156.
- CROOKE ST: Advances in understanding the pharmacological properties of antisenseoligonucleotides. Adv. Pharmacol. (1997) 40:1–49.
- CROOKE ST: Proof of mechanism of antisense drugs. Antisense Nucleic Acid Drug Dev. (1996)6(2):145–147.
- CROOKE ST: Progress in antisense oligonucleotide therapeutics. Ann. Rev. Pharmacol.Toxicol. (1996) 36:107–129.
- ZAMECNIK PC, STEPHENSON ML: Inhibition of Rous sarcoma virus replication and celltransformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA (1978) 75(1):280–284.
- STEPHENSON ML, ZAMECNIK PC: Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Natl. Acad. Sci. USA (1978) 75(1):285–288.
- ECKSTEIN F, GINDL H: Polyribonucleotides containing a phosphorothioate backbone. Eur. J. Biochem. (1970) 13(3):558–564.
- AGRAWAL S, IYER RP: Modified oligonucleotides as therapeutic and diagnostic agents. Curr. Opin. Biotechnol. (1995) 6(1):12–19.
- AGRAWAL S: Antisense oligonucleotides: towards clinical trials. Trends Biotechnol. (1996) 14(10) 376–387.
- BROWN KD: Process specialists see promise in oligonucleotide therapeutics. Genetic Engineering News (1 January 1998) 18:1–2.